相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer vaccines: Moving beyond current paradigms
Jeffrey Schlom et al.
CLINICAL CANCER RESEARCH (2007)
PANVAC™-VF:: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma
Ravi A. Madan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer
Jeanny B. Aragon-Ching et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2007)
A clinical development paradigm for cancer vaccines and related biologics
Axel Hoos et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer
R. Houston Thompson et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy:: The GVAX™ vaccine for prostate cancer
Jonathan W. Simons et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162)
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy
Brian I. Rini et al.
CANCER (2006)
RECIST revisited: A review of validation studies on tumour assessment
P. Therasse et al.
EUROPEAN JOURNAL OF CANCER (2006)
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis
A Gelbard et al.
CLINICAL CANCER RESEARCH (2006)
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer
PM Arlen et al.
CLINICAL CANCER RESEARCH (2006)
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
SJ Antonia et al.
CLINICAL CANCER RESEARCH (2006)
Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy
SF Slovin et al.
CLINICAL CANCER RESEARCH (2005)
Lymphocyte therapy of renal cell carcinoma
Robert O. Dillman
EXPERT REVIEW OF ANTICANCER THERAPY (2005)
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
J Dannull et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer
PM Arlen et al.
JOURNAL OF UROLOGY (2005)
Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables
A Michael et al.
CLINICAL CANCER RESEARCH (2005)
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy
JG Gribben et al.
CLINICAL CANCER RESEARCH (2005)
Multiple costimulatory modalities enhance CTL avidity
JW Hodge et al.
JOURNAL OF IMMUNOLOGY (2005)
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
JL Gulley et al.
CLINICAL CANCER RESEARCH (2005)
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
MEC Lutsiak et al.
BLOOD (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
JL Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside
PB Chapman et al.
CLINICAL CANCER RESEARCH (2004)
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy
AV D'Amico et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing
M Chakraborty et al.
CANCER RESEARCH (2004)
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes
CT Garnett et al.
CANCER RESEARCH (2004)
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (Celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice
HE Zeytin et al.
CANCER RESEARCH (2004)
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
JC Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
S Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells
V Rubio et al.
NATURE MEDICINE (2003)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
M Mercader et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Complementary assets, strategic alliances, and the incumbent's advantage: an empirical study of industry and firm effects in the biopharmaceutical industry
FT Rothaermel
RESEARCH POLICY (2001)
Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
JL Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
